Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
about
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapyGene aberrations for precision medicine against lung adenocarcinomaTargeting EZH2 in cancerPotential targets for ovarian clear cell carcinoma: a review of updates and future perspectivesMammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomicsMolecular Dimensions of Gastric Cancer: Translational and Clinical PerspectivesHistone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyPolycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic ImplicationsEmerging concepts of epigenetic dysregulation in hematological malignanciesMajor clinical research advances in gynecologic cancer in 2015Epigenetic determinants of metastasisPancreatic Cancer, A Mis-interpreter of the Epigenetic LanguagePrediction of Genetic Interactions Using Machine Learning and Network PropertiesZMYND8 Reads the Dual Histone Mark H3K4me1-H3K14ac to Antagonize the Expression of Metastasis-Linked GenesImplementing Genome-Driven Oncology.Interplay of DNA methyltransferase 1 and EZH2 through inactivation of Stat3 contributes to β-elemene-inhibited growth of nasopharyngeal carcinoma cellsIntegrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.Polycomb and trithorax opposition in development and disease.BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.Integrated Molecular Characterization of Uterine Carcinosarcoma.SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancer.Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.Multicellular Tumor Spheroids Combined with Mass Spectrometric Histone Analysis To Evaluate Epigenetic Drugs.Potential therapeutic targets in ARID1A-mutated cancersARID1A gene mutation in ovarian and endometrial cancers (Review).Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesisLoss of Tumor Suppressor ARID1A Protein Expression Correlates with Poor Prognosis in Patients with Primary Breast Cancer.Targeting EZH2 and PRC2 dependence as novel anticancer therapy.Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC.Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast CancerEpigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutationsComprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapiesChromatin Regulators as a Guide for Cancer Treatment ChoiceInhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
P2860
Q26746038-5292D2EA-27CE-409D-84F5-23B2169732A4Q26749348-A71628C4-6E0D-48F0-A191-EDFD38F3B1D4Q26769027-0E374F3F-D986-485F-93EA-78A7709CE0E0Q26775315-ECE365EE-53E9-4D58-AC3A-FD65778D3232Q26776098-D9E4E2B4-EAE4-42C5-8862-2EB7AAC9CD20Q26779725-9BA34E46-3042-459E-A369-1D2691DBDFA6Q26783032-B4E42409-0BD4-4B15-88EF-720865089E97Q26801380-770F379D-2E1A-4316-8FC8-38E1A743E814Q28074522-757DEE2B-1EAB-434C-86E4-0608A8139E4DQ28077183-3377E272-C71D-47A6-AA5F-509BB8AC2C4DQ28079377-0B415F11-C9E5-42AD-A3AC-8667D23C157EQ28079735-D83D8B68-D19B-48D1-BB10-37C3000CBA46Q28084302-D75E587E-1DFC-4C19-9408-BB9C2646190AQ28116530-7E0E3216-A6ED-4172-8469-2DEE96E26671Q30235979-3BFF818A-928F-4971-AAC7-D3540374E6D3Q33674025-2B5EC124-52FE-4C5A-B7F6-35A6DF0C3A9DQ33677392-A37651F7-A1A8-4A51-B54B-79C6C35626ABQ33920032-A8DE3B48-2164-4E6B-AB68-3EC3C14E9F57Q34047394-04C8B871-79F9-4A08-803C-A86EA11ADD8CQ34681051-7133CF45-2E78-461F-B988-11E13C7E740FQ36163245-E0C909D3-CF1A-4ADF-93A5-A21EC734CCAEQ36180735-6187A255-15F8-474F-B7D8-FD70CCF0391DQ36254394-2B5F5E56-5411-4F54-AEF9-03A1541B78F0Q36279590-BED2396C-E2B4-4351-A3C5-E9444310A79EQ36358757-6305CAA7-803D-47CA-9E67-7E0311F18668Q36399463-D22A542C-1E89-4140-951C-4108892C3524Q36424889-1A00BAD8-3E97-42D7-BED9-138F3F5E1328Q36441526-E6BE6625-B965-4C53-9121-9AF6C9DC38E7Q36445523-8E7AE4AA-FC79-45F1-9115-CACCB678DEFAQ36501059-450B803C-322C-480E-9D65-391F429E1B67Q36545265-0764E067-291E-4734-8E30-8AAFE045DB53Q36646352-57E2F656-B7CB-44E7-9C80-AB5F6579B030Q36738866-71027AA4-7035-4C21-8FC8-A6862D74D125Q36768995-3E045CE1-165F-4157-B35A-E5884E77327EQ36836150-DC9EFC04-38A2-4291-8335-93B01291EAFFQ37047704-E0FE50DA-D16F-4A67-9038-69EBEE89B68EQ37075234-F6E1CFA1-FCB5-4F83-89C0-A4C0123F9B9EQ37099828-2CD93E28-AEDD-43C8-BF3A-5159F6B2ADACQ37131530-78D86451-C67A-4507-9D7F-31692C0D38D6Q37230991-3DB3FE65-44A1-49F1-9DB2-0AF0B63EF135
P2860
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Synthetic lethality by targeti ...... vity in ARID1A-mutated cancers
@ast
Synthetic lethality by targeti ...... vity in ARID1A-mutated cancers
@en
Synthetic lethality by targeti ...... vity in ARID1A-mutated cancers
@nl
type
label
Synthetic lethality by targeti ...... vity in ARID1A-mutated cancers
@ast
Synthetic lethality by targeti ...... vity in ARID1A-mutated cancers
@en
Synthetic lethality by targeti ...... vity in ARID1A-mutated cancers
@nl
prefLabel
Synthetic lethality by targeti ...... vity in ARID1A-mutated cancers
@ast
Synthetic lethality by targeti ...... vity in ARID1A-mutated cancers
@en
Synthetic lethality by targeti ...... vity in ARID1A-mutated cancers
@nl
P2093
P2860
P3181
P356
P1433
P1476
Synthetic lethality by targeti ...... vity in ARID1A-mutated cancers
@en
P2093
Andrew V Kossenkov
Azat Garipov
David C Schultz
David W Speicher
Ie-Ming Shih
Jose R Conejo-Garcia
Katherine M Aird
Michael Amatangelo
P2860
P2888
P304
P3181
P356
10.1038/NM.3799
P407
P577
2015-02-16T00:00:00Z